Treatment Adjusteda mean (95% CI) difference from placebo at 6 weeks Trough FEV1 n Adjusted mean (SE) Mean (SE) P value 95% CI Study 1222.39           Placebo 99 -0.043 (0.020)       Olodaterol 5 µg 100 0.090 (0.020) 0.133 (0.019) <0.0001 0.096, 0.170 Olodaterol 10 µg 99 0.104 (0.020) 0.147 (0.019) <0.0001 0.110, 0.184 Tiotropium 18 µg 99 0.054 (0.020) 0.097 (0.019) <0.0001 0.060, 0.134 Study 1222.40           Placebo 105 0.003 (0.019)       Olodaterol 5 µg 115 0.137 (0.019) 0.134 (0.019) <0.0001 0.097, 0.171 Olodaterol 10 µg 107 0.146 (0.019) 0.143 (0.019) <0.0001 0.105, 0.181 Tiotropium 18 µg 112 0.161 (0.019) 0.158 (0.019) <0.0001 0.120, 0.195 FEV1 AUC0–3           Study 1222.39           Placebo 99 -0.045 (0.019)       Olodaterol 5 µg 100 0.161 (0.019) 0.206 (0.019) <0.0001 0.170, 0.243 Olodaterol 10 µg 99 0.170 (0.019) 0.215 (0.018) <0.0001 0.179, 0.252 Tiotropium 18 µg 99 0.137 (0.019) 0.182 (0.019) <0.0001 0.146, 0.219 Study 1222.40           Placebo 105 0.011 (0.020)       Olodaterol 5 µg 115 0.225 (0.019) 0.214 (0.019) <0.0001 0.178,0.251 Olodaterol 10 µg 106 0.255 (0.020) 0.245 (0.019) <0.0001 0.208,0.282 Tiotropium 18 µg 112 0.246 (0.019) 0.235 (0.019) <0.0001 0.199, 0.271 FEV1 AUC0–24           Study 1222.39           Placebo 99 -0.075 (0.020)       Olodaterol 5 µg 100 0.083 (0.020) 0.158 (0.019) 0.158 (0.019) 0.121, 0.196 Olodaterol 10 µg 99 0.117 (0.020) 0.192 (0.019) <0.0001 0.155, 0.230 Tiotropium 18 µg Tiotropium 18 µg 0.073 (0.020) 0.148 (0.019) <0.0001 0.110, 0.185 Study 1222.40           Placebo 105 -0.033 (0.019)       Olodaterol 5 µg 115 0.142 (0.018) 0.175 (0.017) <0.0001 0.141, 0.208 Olodaterol 10 µg 107 0.158 (0.018) 0.191 (0.017) <0.0001 0.157, 0.225 Tiotropium 18 µg 112 0.159 (0.018) 0.192 (0.017) <0.0001 0.159, 0.226

Table 4: Secondary efficacy end point: FEV1 responses (L) after 6 weeks.